Session: SAT 449-497-Thyroid Neoplasia & Case Reports
Poster Board SAT-482
A 45 year old male patient with past medical history of Graves’ disease with severe ophthalmopathy was referred to endocrine clinic. His symptoms started with dry eyes several years ago without associated hypermetabolic symptoms. Further investigation revealed hyperthyroidism; he was started on methimazole. Thyroid stimulating immunoglobulin was 484 %( reference: <140%, Method: immunoassay). Thyroid scan with I-123 sodium iodide showed uptake of 28.3 percent at 24 hours, and showed large area of intense activity mid and lower left thyroid lobe with suppression of uptake in rest of the thyroid gland. Thyroid ultrasound showed heterogeneous well-defined 1.3x1.0x1.0 cm left mid lower pole nodule. These findings are suggestive of a rare variant of Marine-Lenhart syndrome.
Graves’ disease is thought to be caused by autoantibodies stimulating the TSH receptors. Thyroid nodules associated with Graves’ disease have been reported with the incidence between 25 to 30%, most of which are cold nodules. The incidence of Graves’ disease accompanied by hot nodules ranges from 2.7 to 4.1%.These rare cases with Graves’ disease with accompanying functioning thyroid nodules are known Marine-Lenhart syndrome. Most reported cases of Marine-Lenhart syndrome are Graves’ disease with multiple hyperfunctioning nodules. Our case represents an unusual variety in which Graves’ disease with a hyperfunctioning solitary nodule was associated with suppression of the remaining gland. Acquired mutations resulting in constitutively activated TSH receptors and presence of anti TSH receptor autoantibodies might be responsible for the development of Marine-Lenhart syndrome. Cases have been published suggesting possible development of hyperfunctioning nodules in Graves’ disease after ablative treatment with Iodine 131. Marine-Lenhart syndrome with a hot nodule containing papillary thyroid microcarcinoma has also been described, which upon total thyroidectomy revealed multifocal involvement.
Nothing to Disclose: RP, PS, ASS, GB, NM
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters